+183%

est. 2Y upside i

HealthcareSeries A

Avelios is a modern and modular hospital information system bringing together documentation, administration, patient portals, AI solutions and more.

Rank

#66

Sector

Healthtech

Est. Liquidity

~4Y

Data Quality

Data: Medium

Avelios offers a strong growth narrative with a modern HIS platform, but the equity case is tempered by high incumbent threat and limited near-term liquidity.

Last updated: July 19, 2026

Bull (10%)+365%

Multiple holds at 8x due to successful IPO window or category leadership; projected revenue $53.3M yields exit value $426M, net of 20% dilution.

Base (50%)+244%

Multiple converges to 6x, consistent with public comps; exit value $320M, net of 20% dilution.

Bear (40%)+62%

Multiple compresses to 3x due to incumbent competition and slower growth; exit value $160M, net of 20% dilution, preference stack not triggered.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

114%

Total funding of $33.3M represents 38% of current valuation, indicating severe preference overhang.

Dilution Risk

high

Likely need for additional capital within 24 months given burn rate and early stage.

Secondary Liquidity

none

No secondary market activity observed; IPO or acquisition needed for liquidity.

Questions to Ask at the Interview

Strategic questions based on Avelios's data — designed to show you've done your homework.

  • 1

    “How do you plan to differentiate against Epic and Cerner's installed base over the next 2 years?”

  • 2

    “What is the path to profitability given the current burn rate and subscription model?”

  • 3

    “What is the expected timeline for an IPO or acquisition, and how does that align with employee liquidity?”

Community

Valuation Sentiment

Our model estimates +183% upside. What do you think?

Anonymous. Do not share material non-public information.


Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.